SCHEMBL1598884

SCHEMBL1598884

OC1(c2cccc(Sc3ccc4c(ccc5nnc(-c6ccccc6)n54)c3)c2)CCOCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.37
LMNA P02545 2/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
THRB P10828 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALOX5 P09917 12/20 0.36
LRRK2 Q5S007 2/20 0.35
PDE2A O00408 1/20 0.34
PDE10A Q9Y233 1/20 0.34
CYP1A2 P05177 2/20 0.33
MAPT P10636 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1599196 0.90 LRRK2 (0.40) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1598349 0.87 PDE2A (0.39) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1599252 0.87 ALOX5 (0.52) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1599056 0.86 PIK3CD (0.38) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1599824 0.86 ALOX5 (0.40) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1600188 0.82 RECQL (0.35) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1599103 0.81 RECQL (0.35) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1599093 0.80 PIK3CD (0.36) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1599488 0.80 ALOX5 (0.35) RECQLLMNAHPGDKDM4EALDH1A1
SCHEMBL1599272 0.79 MAPK14 (0.37) RECQLLMNAHPGDKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2011-05-12 US claimed
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-07-26 US claimed
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2011-05-12 US disclosed
US-7919621-B2 Tricyclic inhibitors of 5-lipoxygenase AMIRA PHARMACEUTICALS, INC. (US) 2011-04-05 US disclosed
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE AMIRA PHARMACEUTICALS, INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173508-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B RECQL 1884/4885LMNA 686/4885HPGD 69/4885
US-20110112106-A1 TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE ALOX5, ALOX15, ALOX15B RECQL 1884/4885LMNA 686/4885HPGD 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.